Abstract
Acute leukemias in children aged under 1 year has different clinical manifestations as compared to patients of older age groups. The prognostic values of ALL and AML in children under 1 year are different. In ALL there are additional independent risk factors which worsen the prognosis. Clinical researches in the field of infant acute leukemia is still under develop and making a significant contribution to the understanding of the biology of leukemogenesis and therapy. The results of therapy in different research groups were comprised: POG, CCG, COG (USA), JPLSG (Japan), Interfant (BFM, researchers from New Zealand, Australia and the USA). The difference of the results led to discrepancy regarding the role of allo-HSCT in the infants treatment. In Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, the 10-year OS after allo-HSCT in the pediatric group with high-risk infant leukemias was 55 %, in the group of patients with restructuring of the MLL gene – 53 % versus 59 % without MLL gene. The results of allo-HSCT depended on the disease stage at the time of treatment, in I–II CR 5-year OS was 79 % (n = 35), in III–IV CR or progression –16 % (n = 20).
Highlights
Результаты алло-ТГСК зависели от стадии заболевания в момент ее проведения, в I–II полной ремиссии (ПР) 5-летняя общая выживаемость (ОВ) составила 79 % (n = 35), в III–IV ПР или прогрессии – 16 % (n = 20)
Acute leukemias in children aged under 1 year has different clinical manifestations as compared to patients of older age groups
Clinical researches in the field of infant acute leukemia is still under develop and making a significant contribution to the understanding of the biology of leukemogenesis and therapy
Summary
Горбачевой 10-летняя общая выживаемость (ОВ) после алло-ТГСК в группе детей с младенческим лейкозом высокой группы риска составила 55 %, в группе больных с перестройкой гена MLL – 53 % против 59 % без его вовлечения. In Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, the 10-year OS after allo-HSCT in the pediatric group with high-risk infant leukemias was 55 %, in the group of patients with restructuring of the MLL gene – 53 % versus 59 % without MLL gene. (Med.), Head of the 1st Pediatric Transplant Department at Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, e-mail: paina@mail.ru; https://orcid.org/ 0000-0001-7263-4326
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Russian Journal of Pediatric Hematology and Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
